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1. Introduction
This chapter reviews the clinical presentation, histopathology, immunoprofile and molecular
features of Langerhans cell neoplasms of the skin including Langerhans cell histiocytosis
(LCH) and its malignant counterpart, Langerhans cell sarcoma (LCS). Biopsy of the skin is a
useful method to confirm LCH/LCS diagnosis, as cutaneous involvement is seen in more than
50% cases. Skin can be the only presenting site of LCH, but it is usually seen as an integral part
of multisystemic disease involvement.
Langerhans cells (LC) are bone marrow-derived antigen presenting cells [1]. Although LC,
dendritic cells and monocytic/histiocytic cells share a common multipotential progenitor cells
that reside in the bone marrow, to the date, myeloid derived macrophages and dendritic cells
constitute divergent lines of differentiation from bone marrow precursors [2]. However, recent
evidence demonstrates that LC can be generated from lymphoid-committed CD4low precur‐
sors, suggesting the role of lineage plasticity/ trans-differentiation and clonal infidelity [3-4].
LC can be found in the epidermis and mucosal lining of multiple organs including cervix,
vagina, stomach and esophagus. The specific immunophenotypic profile is helpful distin‐
guishing LCs, as they can express CD1a and langerin (CD207); in addition the detection of
Birbeck granules, seen in both pathological and resting LC is a prominent feature [5].
LCH encompasses a spectrum of disease characterized by an uncontrolled proliferation of LC
[5]. The etiology of LCH/LCS is unknown in most cases, and there is not clear understanding
of the pathogenesis. Although LCH is believed to be a clonal proliferation of LC [2, 6], the exact
nature is controversial, as pulmonary LCH is thought to be a reactive/inflammatory disorder
rather than a neoplastic process, and spontaneous remissions have been documented [7-8]. In
a recent study of well characterized LCH cases, 30% had clonal immunoglobulin heavy chain
(IGH@), immunoglobulin kappa light chain (IGK@) or T-cell receptor gamma (TCRG@) gene
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rearrangements, suggesting a close relationship between LCH and lymphoid lineage [3].
Additional data that suggests LCH is in fact a clonal disease is the presence of specific
mutations such as BRAF V600E, which have been found in up to 76% of tumors in children
<10 years of age [7, 9].
2. Langerhans cell histiocytosis
2.1. Clinical presentation
LCH can affect a wide range of patients, including neonates, young children and adults. In
children younger than 2 years of age, cutaneous involvement is the most common presentation
[10]. In neonates and young infants, skin is frequently involved, as solitary or multiple papules
or nodules with ulceration or necrosis. Patients usually present with dermatitis-like lesions
that involves scalp, trunk, intertriginous skin folds and perineum with brownish/whitish
papules covered with scales and crust [11]. In neonates, eruptions may affect most of the body
surface. In contrast, in adults, LCH with initial presentation occurring in the skin is unusual
[12].
LCH can be localized, multifocal or multisystemic. Systemic disease can involve organs such
as bone marrow, liver, central nervous system, gastrointestinal tract, lungs and spleen.
Systemic forms include Letterer-Siwe disease (with skin, lymph node and visceral involve‐
ment) and Hand-Schuller-Christian syndrome (in young children).
Congenital disease is rare and often clinically benign, presented in the form of reticulohistio‐
cytosis (Hashimoto-Pritzker disease) as a self-healing or regressive form of the disease.
Congenital disease usually presents at birth or in the first few weeks of life as a widespread
cutaneous eruption of red-brown nodules that resolves spontaneously [10, 13], although it can
rarely be associated with multiorgan involvement [10, 14].
2.2. Histopathology
Recognition of morphologic and immunohistochemical features is essential to establish both
the diagnosis and the LC origin. The skin shows a predominant diffuse papillary dermal
infiltrate composed of large cells with lobulated, eccentric grooved nuclei with “coffee-bean
shape” appearance and inconspicuous nucleoli. The epidermis may be ulcerated and epider‐
motropism is commonly seen (FIGURE 1).
A variable polymorphic infiltrate of eosinophils, lymphocytes, plasma cells and neutrophils
is usually admixed with neoplastic cells. Eosinophils are often but not invariably present, and
sometimes can be quite numerous, masking LC (FIGURE 2). Mitotic activity may be brisk. In
some cases, LC may resemble histiocytes or Touton cells. Sometimes, a granulomatous reaction
with histiocytic infiltrate can be identified.
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Figure 2. Histological features of Langerhans Cell Histiocytosis (LCH). Skin with inflammatory infiltrate composed of
Langerhans cells admixed with abundant eosinophils and neutrophils.
Figure 1. Histological features of Langerhans cell histiocytosis (LCH). A and B. Skin shows dermal infiltrate with epider‐
motrophism. C. Cells with grooved nuclei.
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2.3. Immunoprofile and electron microscopy
Identification of LC may be done by routine hematoxylyn-eosin alone. However, confirmation
requires positive staining for CD1a, S100 and langerin (CD207) (FIGURE 3), with variable
expression of CD68 and usually absence of CD163 stain.
Figure 3. Histological features and immunophenotypic profile of Langerhans Cell Histiocytosis (LCH). A. Skin with der‐
mal infiltrate and epidermotrophism. B. Langerin immunostain (CD207) highlights neoplastic Langerhans Cells (LC). C.
LC are positive for CD1a.
A novel antibody, JL1, has been described as a specific marker in LCH. Interestingly, LC in the
epidermis of normal skin express langerin but not JL1; however both antibodies are expressed
in inflamed skin [5]. In addition, a recent specific antibody to detect BRAFV600E mutation in
LCH by immunohistochemistry is identified that can be used for routine screening [15]. E-
cadherin expression has been reported as well (FIGURE 4). Electron microscopy can be used
to demonstrate intracytoplasmic Birbeck granules of approximately 300 nm with a tennis-
racket shape.
2.4. Differential diagnosis
Related and unrelated histiocytic disorders and benign LC proliferations lead to diagnostic
pitfalls in LCH. Localized LC proliferations are seen in a vast number of skin conditions that
may be reactive, but are often neoplastic. Similarly, histiocytic infiltrates in the dermis are very
common, and appear in response to inflammatory conditions, infections and neoplasms.
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LC microabscesses can sometimes be seen in the epidermis of spongiotic dermatitides and
lichenoid dermatitis. LC are usually seen as small to large collection of pale staining/mono‐
nuclear cells, positive for CD1a and S100. These aggregates can mimic Pautrier’s microabs‐
cessess in mycosis fungoides [16].
In children with eczematous eruptions and histiocytic infiltrates, langerhans cell hyperplasia
(LCHP) has to be ruled out. LCHP can mimic LCH and has been reported in cases of human
scabies, arthropod bite reaction, contact dermatitis and pytiriasis lichenoides and usually cells
express CD1a and S100 [17-20]. The increased in LC in the dermis can be explained by the
antigenic stimulation and cutaneous trauma that produce LC migration into the skin, espe‐
cially when occurs in perivascular areas. Therefore, the clinical context in which the lesion or
proliferation arises is important in the differential diagnosis.
Likewise, reactive histiocytosis in the skin can be seen secondary to foreign body reactions to
implants and polarizable material is often identified [21]. LC can also mimic dermal histiocytes
found in inflammatory and infectious conditions (mycobacteria, fungal and parasitic process‐
es), thus clinicopathologic correlation, immunostains and appropriate special stain can be
helpful in the differential. Eosinophils, a common finding in LCH can also be seen in a variable
number of conditions such as drug eruptions, urticaria and wells syndrome.
Furthermore, a group of conditions named as non-Langerhans cells histiocytosis (N-LCH) can
mimic LCH. These entities are characterized by accumulation of histiocytes and immunohis‐
tochemistry is a useful adjuvant for the distinction; some of them will be describe in the
following pages [22].
Figure 4. Immunoprofile of Langerhans Cell Histiocytosis. E-cadherin is positive in scattered LC.
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Rosai-Dorfman disease (RDD) is a self-limiting histio-proliferative disorder that can compro‐
mise almost any organ, and occasionally involves the skin [23]. Cutaneous RDD is character‐
ized by the presence of a dense infiltrate of foamy histiocytes with emperipolesis surrounded
by a background of lymphocytes, plasma cells and neutrophils. Occasionally, eosinophils can
be increased [24]. Histiocytic cells in RDD usually express CD68 and S100 and lack of CD1a
staining.
The Juvenile Xantogranuloma (JXG) family is a spectrum of conditions characterized by
expression of factor XIIIa, CD68, CD163, fascin and CD14 but lack immunoexpression for CD1a
and S100 [22, 24]. The clinical setting is useful to differentiate the entities. JXG is a common
member of this family. JXG presents as a solitary skin lesion, most commonly seen throughout
the first two decades of life, although some cases have been described in extracutaneous sites.
JXG is characterized by circumscribed dermal nodules composed of true foamy histiocytes and
Touton giant cells. Touton giant cells are seen in the majority of cases, and show a wreath of
nuclei around a homogenous eosinophilic cytoplasm and xanthomatous periphery (FIGURE
5) [22, 25]. JXG has been reported associated with neurofibromatosis type 1, hemophagocytic
lymphohistiocytosis and juvenile myelomonocytic chronic leukemia [26-27].
Figure 5. Juvenile Xantogranuloma (JXG). A. Dome shape lesion with dermal infiltrate. B. Touton giant cells in JXG.
Erdheim-Chester disease (ECD) may also be confused by LCH. ECD is a systemic disease
which usually presents with lung and symmetrical long bony lesions. It can also involve the
skin and clinically appears with pruritic rash, xanthelasma and eyelid xanthomas, in a
background of normal lipid profile [28]. ECD displays collections of enlarged histiocytes with
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clear cytoplasm. ECD can be differentiated from LCH by immunohistochemical studies; ECD
cells usually express CD68, CD163, fascin, while negative for S100, langerin and CD1a. Birbeck
granules are absent [22].
Finally, a hybrid entity, indeterminate cell histiocytosis (immature dendritic cells) is an
uncommon disease with features between LCH and N-LCH. Although it shows immunophe‐
notypic similarities with LCH such as CD1a positivity and variable expression of S100 and
CD68, lacks of Birbeck granules by electron microscopy.
Malignant neoplasms such as histiocytic sarcoma (HS), myelomonocytic leukemia, anaplastic
large cell lymphoma and mast cell proliferations should also be considered into the differential
diagnosis [24, 29]. HS is a malignant proliferation of mature histiocytes. Skin presentation is
often seen, although multisystemic involvement is a frequent feature. Histologically, HS show
cytologic atypia, pleomorphism and mitotic activity; the immunophenotypic profile demon‐
strates that the malignant cells are usually positive for CD68, CD163, CD14, CD4, CD11c and
lysozyme. Birbeck granules are not seen [30].
Interestingly, cases of LCH have been found in association with malignancy including solid
tumors and hematologic neoplasms [31-32]. In a recent study, adult patients with LCH
presenting in the skin have shown an increased risk of a second hematological malignancy [12].
They can present with a solitary papule/nodule or multiple reddish-brown papules. The
literature includes reports of LCH and non-Hodgkin lymphoma, Hodgkin lymphoma, acute
lymphoblastic leukemia [33] and acute myeloid leukemia (AML) [31, 34-38]. One of the current
theories that could explain the association between LCH and AML relates to trans-differen‐
tiation of hematopoietic lineages as LC, dendritic cells, and monocytic/histiocytic cells share
common multipotential progenitor cells that reside in the bone marrow [39-42]. These cases
suggest a clonal relation between the two neoplastic diseases and support the theories of
lineage plasticity in mature and immature lymphoid tumors.
2.5. Prognosis
LCH is a heterogeneous disease with different outcomes including self healing-limited and
life-threatening or fatal disease [14]. Clinical staging is a prognostic marker in neonates and
infants [14, 43]. Unifocal/localized disease has a good prognosis and long term survival. In
contrast, the clinical course and the prognosis of multifocal and multisystemic disease are
difficult to predict. When disseminated disease is present at the time of diagnosis, the disease
is usually associated with poor outcome [14, 43]. Therefore, identification of specific biomark‐
ers is needed in order to determine who will have limited disease and who will benefit from
systemic therapy.
Using OncoMap, the activating mutation BRAF V600E mutation has been recently identified
as a recurrent molecular genetic aberration in LCH, however, its clinical significance is still
unknown [7, 9, 14]. BRAF V600E mutations have been identified in LCH and ECD, however,
they have not seen in RDD and JXG [44]. Interestingly, inhibition of BRAF V600E may be used
in the near future as a therapeutic target for LCH similar to what is being done for melanoma,
gliomas and hairy cell leukemia. Patients with positive mutation status and protein expression
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by screening may be allowed for protocol or clinical trial entry with use of Zelboraf (vemura‐
finib), an FDA approved therapy. Recently, a variant BRAF V600D mutation has been reported
in congenital, benign, self-regressive LCH [14]. E-cadherin expression was found as a marker
of good prognosis and limited disease, however, the results have not been validated in
separated studies [10, 45]. The role of Ki67 as a prognostic marker is limited. One of the most
common abnormalities seen in LCH is TP53 over-expression (FIGURE 6); however, TP53
mutations have not been identified [7, 9, 46].
Figure 6. TP53 over-expression in Langerhans Cell Histiocytosis (LCH)
2.6. Treatment
Patients require complete clinical history, physical examination, and a comprehensive
laboratory and radiographic evaluation [47]. The Histiocyte Society recommends that in order
to determine the adequate research protocol, patients should be stratified based upon exten‐
sion of the disease (unifocal, multifocal/multysistemic), involvement of risk organs (hemato‐
lymphoid including spleen and liver) and central nervous system risk lesions [48-49]. Patients
with unifocal disease limited to the skin require follow up-and usually no additional treatment
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is necessary as spontaneous regression may occur. Topical therapy with steroids or PUVA may
be used [48]. In cases of multiorgan/multisystemic involvement, the treatment is controversial
as those patients have a variable clinical course; it includes systemic chemotherapy with
assessment of clinical response after the first 6 weeks of treatment. Monoclonal antibodies are
under research. In one large study, Vinblastine with or without prednisolone was the most
common chemotherapy regimen, and the overall survival and event free survival rates were
84% and 51.5%, respectively with a medium follow-up time of 8 years [50]. The LCHIII
treatment protocol is a common strategy used in patients with multiorgan involvement [51].
Targeted therapy with vemurafenib, an inhibitor of mutated BRAF, has been used in few
patients with LCH harboring BRAF V600E mutation [52].
3. Langerhans cell sarcoma
3.1. Clinical presentation
Thirty one cases of LCS have been reported to date [53]. Skin can be a single site involved by
LCS or can be seen as part of widespread disease. Cutaneous involvement is present in more
than half of cases. Multiorgan involvement includes lymph node, lungs, liver, spleen and bone.
Skin biopsy is an accessible and a useful way to demonstrate malignant LC. LCS occurs in all
age groups with a male:female ratio 1:1. LCS can appear as an increasingly progressive
malignant disease followed by multiple LCH recurrences, de novo and with underlying
myeloproliferative disease [53-55]. De novo or primary LCS has been reported exclusively in
adults, without previous evidence of LCH. In a recent publication, a case of trans-differentia‐
tion of acute B-lymphoblastic leukemia into a LCS has been documented, as both show
identical IGH@ gene rearrangements [54].
3.2. Histopathology
Skin biopsy usually shows an infiltrative and poorly defined high grade malignant neoplasm
composed of large cells with grooved nuclei, granular chromatin, prominent nucleoli and high
mitotic rate. Although inflammatory infiltrate can be present and abundant, especially if there
is associated necrosis, eosinophils are usually scattered. Epidermis can be ulcerated and
epidermotropism is seen [2, 55]. (FIGURE 7)
3.3. Immunoprofile and electron microscopy
Malignant LC are usually positive for CD1a, S100 and Langerin (CD207) (FIGURE 8). There is
lack of reactivity for T and B cell antigens. Neoplastic cells have a high proliferative Ki67 index
and overexpress p53. CD56 /neural cell adhesion molecule (NCAM) positivity has been found
expressed in LCS [56]. A broad panel of immunohistochemical stains is used to confirm LC
due to the atypical features of the neoplasm, and electron microscopy is usually performed for
identification of intracytoplasmic Birbeck granules.
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Figure 8. Immunoprofile of Langerhans Cell Sarcoma (LCS). A. Langerin (CD207) expression in cells with malignant
features. Numerous mitotic figures are identified. B. Malignant cells retain CD1a expression.
Figure 7. Histological appearance of Langerhans Cell Sarcoma (LCS). A. Dermal infiltrate of large atypical cells with
epidermotrophism. B. Bizarre and pleomorphic cells with abundant mitotic figures and lack of cohesiveness. C. De‐
tailed figure of LCS cells with prominent intranuclear inclusions.
Skin Biopsy - Diagnosis and Treatment36
3.4. Differential diagnosis
Because of the marked pleomorphism and cytologic atypia, hematologic and nonhematologic
entities must be considered in the differential diagnosis including malignant melanoma,
carcinoma, mesenchymal malignant neoplasms and lymphomas with anaplastic features.
Pleomorphic large cells may be mistaken for malignant melanoma, which shares S100
positivity but also expresses other melanocytic markers. LCS comprises cells with bizarre
pleomorphic nuclei and abundant cytoplasm mimicking hematolymphoid neoplasms
including anaplastic large cell lymphoma, anaplastic diffuse large B-cell lymphoma, plasma
cell neoplasm with anaplastic features, lymphomatoid papulosis, peripheral T cell lymphoma
and myeloid sarcoma (FIGURE 9) (TABLE 1) [55]. In those cases, immunohistochemical and
molecular features are useful to distinguish the cell of origin.
Figure 9. Myeloid Sarcoma. A. Skin shows a diffuse dermal infiltrate composed of malignant cells. B. Features of neo‐
plastic cells with promyelocytic differentiation. C. CD34 stain is positive in the majority of cells. D. Myeloperoxidase
(MPO) positivity in tumor cells.
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DIFFERENTIAL DIAGNOSIS Immunohistochemical marker
Melanoma S100+, Melan A+, HMB45+
Anaplastic large cell lymphoma CD30+, ALK+/-, EMA+, CD3-/+, CD43+
Histiocytic Sarcoma CD68+, CD163+, CD14+, CD4+, lysozyme, S100+/-
Follicular Dendritic Cell Sarcoma CD21+, CD23+, CD35+, CD68+/-, S100+/-, Clusterin+, CD45+/-
Interdigitating Dendritic Cell Sarcoma S100+, CD21-, CD35-, CD1a-, fascin +, CD68-/+
Myeloid Sarcoma CD34+, CD117+, MPO+, CD68+, lysozyme+
Table 1. Langerhans Cell Sarcoma (LCS) - Differential Diagnosis
3.5. Prognosis and treatment
Currently, no specific marker has demonstrated to predict prognosis in LCS. In a study, CD56
expression was associated to poor prognosis and the results have not been validated in a
different set of patients [56]. Despite combination chemotherapy/radiotherapy and surgery,
LCS is an aggressive high grade malignancy with poor prognosis, frequent recurrences and
short survival, usually resulting in death within 1 year [2, 53, 55].
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